Fat intake after prostate cancer diagnosis and mortality in the Physicians' Health Study
- PMID: 26047644
- PMCID: PMC4499006
- DOI: 10.1007/s10552-015-0606-4
Fat intake after prostate cancer diagnosis and mortality in the Physicians' Health Study
Abstract
Purpose: Diet after prostate cancer diagnosis may impact disease progression. We hypothesized that consuming saturated fat after prostate cancer diagnosis would increase risk of mortality, and consuming vegetable fat after diagnosis would lower the risk of mortality.
Methods: This was a prospective study among 926 men with non-metastatic prostate cancer in the Physicians' Health Study who completed a food frequency questionnaire a median of 5 years after diagnosis and were followed for a median of 10 years after the questionnaire. We examined post-diagnostic saturated, monounsaturated, polyunsaturated, and trans fat, as well as animal and vegetable fat, intake in relation to all-cause and prostate cancer-specific mortality. Hazard ratios (HR) and 95 % confidence intervals (CI) were estimated using multivariate Cox proportional hazards regression.
Results: We observed 333 deaths (56 prostate cancer deaths) during follow-up. Men who obtained 5 % more of their daily calories from saturated fat and 5 % less of their daily calories from carbohydrate after diagnosis had a 1.8-fold increased risk of all-cause mortality (HR 1.81; 95 % CI 1.20, 2.74; p value 0.005) and a 2.8-fold increased risk of prostate cancer-specific mortality (HR 2.78; 95 % CI 1.01, 7.64; p value 0.05). Men who obtained 10 % more of their daily calories from vegetable fats and 10 % less of their daily calories from carbohydrates had a 33 % lower risk of all-cause mortality (HR 0.67; 95 % CI 0.47, 0.96; p value 0.03).
Conclusions: Among men with non-metastatic prostate cancer, saturated fat intake may increase risk of death and vegetable fat intake may lower risk of death.
References
-
- Ries L, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review 1975–2005. Bethesda, MD: National Cancer Institute; 2007. pp. Based on November 2007 SEER data submission.
Publication types
MeSH terms
Substances
Grants and funding
- CA167552/CA/NCI NIH HHS/United States
- R01 CA090598/CA/NCI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- CA90598/CA/NCI NIH HHS/United States
- CA58684/CA/NCI NIH HHS/United States
- R01 CA058684/CA/NCI NIH HHS/United States
- R01 HL035464/HL/NHLBI NIH HHS/United States
- R01 CA040360/CA/NCI NIH HHS/United States
- CA40360/CA/NCI NIH HHS/United States
- CA141298/CA/NCI NIH HHS/United States
- R01 HL034595/HL/NHLBI NIH HHS/United States
- R01 CA042182/CA/NCI NIH HHS/United States
- HL35464/HL/NHLBI NIH HHS/United States
- R01 HL026490/HL/NHLBI NIH HHS/United States
- CA42182/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- R01 CA034944/CA/NCI NIH HHS/United States
- R01 CA141298/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical